Efficacy and safety of Hetrombopag for platelet engraftment after allogeneic hematopoietic stem cell transplantation – a prospective, multicenter, randomized controlled clinical trial

Efficacy and safety of hetrombopag for platelet engraftment after allogeneic hematopoietic stem cell transplantation – a prospective, multicenter, randomized controlled clinical trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057764

Enrollment

Unknown

Registered

2022-03-16

Start date

2022-03-08

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:hetrombopag was taken orally

Control group:recombinant human thrombocytopeoietin (TPO) was injected subcutaneously

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients receiving HLA allogeneic hematopoietic stem cell transplantation (including haploid, homologous); 2. Aged >18 years, no gender limit; 3. ECOG score) <=1 score; 4. Patients with follow-up conditions; 5. No serious systemic important viscera function damage.

Exclusion criteria

Exclusion criteria: 1. Patients who failed to take TPO agonist before transplantation; 2. Patients with digestive tract symptoms, disturbance of consciousness and unable to take oral drugs during transplantation; 3. Other reasons for not being included in the study.

Design outcomes

Primary

Measure	Time frame
Mean time to successful platelet reconstitution with hetrombopag after transplantation;	—

Secondary

Measure	Time frame
The safety of hetrombopag after use;Effective rate of platelet reconstitution success;	—

Countries

China

Contacts

Public ContactZhang Xi

yimeifeng@163.com+86 23 68763198

Outcome results